We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Analytik Jena Acquires California-Based UVP

By LabMedica International staff writers
Posted on 30 Apr 2013
Analytik Jena, AG (Jena, Germany) recently acquired all of the outstanding shares of UVP, LLC (Upland, CA, USA), including its subsidiary, Ultra-Violet Products, Ltd. More...
(Cambridge UK).

UVP is a leading manufacturer of bioimaging systems for applications in proteomics, genomics, animal and plant sciences. The company also develops ultraviolet (UV) products, light sources, and laboratory equipment such as hybridization ovens, transilluminators, crosslinkers, and polymerase chain reaction (PCR) hoods.

The acquisition of UVP allows Analytik Jena to strengthen its presence in the US market and expand its product range. “With the acquisition of UVP, we are significantly expanding our business activities in the Life Science unit and are laying an excellent basis for developing our successful business model in the US and neighboring regions. Here, we are combining efficient sales structures, a well-coordinated product portfolio, and broad technological expertise in the respective core segments. Further extensive synergies are to arise, especially in sales in Europe and Asia. With UVP, Analytik Jena also gains a production plant in the US dollar currency area,” remarked Klaus Berka, CEO of Analytik Jena, AG.

Analytik Jena is a provider of analytic technology, life-science systems for bioanalytic applications, and high-end optical consumer products. With UVP’s incorporation into Analytik Jena’s life-science business unit, many synergies are expected.

According to Leighton Smith, UVP’s president and CEO, “UVP has an opportunity to contribute significantly to the growth and profitability of Analytik Jena’s Life Science business unit. Our combined manufacturing expertise, portfolio of products and distribution channels open up new market opportunities, and begins an exciting new chapter in UVP’s history of providing innovative products and solutions to our customers.”

Related Links:

Analytik Jena
UVP



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.